Phase 3 Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy and Safety Results in Patients with Generalized MG (PL5.005)
To investigate the efficacy and safety of inebilizumab, a monoclonal antibody targeting CD19+ B-cells, in generalized myasthenia gravis (gMG).
Authors
- Nishi Rampal (ORCID: https://orcid.org/0009-0008-2285-0360)
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Mikhail Rojavin (ORCID: https://orcid.org/0000-0002-9010-2865)
- Michael Benatar (ORCID: https://orcid.org/0000-0003-4241-5135)
- James F. Howard (ORCID: https://orcid.org/0000-0002-7136-8617)
- Emma Ciafaloni (ORCID: https://orcid.org/0000-0002-3925-3289)
- Yuehua Wu (ORCID: https://orcid.org/0000-0002-8858-1289)
- Maria Isabel Leite (ORCID: https://orcid.org/0000-0003-4407-5066)
- Fengming Tang
- Richard J. Nowak
- John Vissing
- Sue Cheng
Institutions
- University of North Carolina at Chapel Hill (US)
- University of Copenhagen (DK)
- Amgen (United States) (US)
- University of Miami (US)
- Yale University (US)
- University of Oxford (GB)
- National Hospital Organization Hanamaki Hospital (JP)
- University of Rochester (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211217
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00